which include the occurrence of different cardiomyopathies caused by the same genetic mutation (in unrelated and related individuals), the same cardiomyopathy resulting from many different mutations, and the evolution of one disease phenotype into another over time. Over the last few years, genetic association studies have taken advantage of the remarkable improvements in high density genotyping and significantly contributed to the discovery of novel loci for cardiomyopathies including HCM and DCM. Since the 1970s, Sanger sequencing has remained the gold standard for detecting sequence variants in patients. Despite its high reliability and partial automation, it is expensive and relatively slow method. Next-generation sequencing (NGS) represents the dawn of a new diagnostic era, by providing fast and reliable testing for multiple genes at a relatively low cost. 10 Accordingly, high-throughput mutation screening in disease genes for DCM, HCM, and other cardiomyopathies is now possible using target enrichment followed by next -generation sequencing (NGS), yielding precise detection of sequence variants and mutations in multiple disease-relevant genetic loci in parallel, whilst reducing the manual handling steps needed in traditional sequencing assays. 11 
| MATERIALS AND METHODS

| Study population
Sixteen individuals with established cardiomyopathy recruited from 
| Next-generation sequencing
An amount of at least 2 μg of genomic DNA at a minimum concentration of 50 ng/μL extracted from patients was used for whole exome 
| Variant filtering and classification
The pair-end reads were quality trimmed and aligned with the human genome reference sequence (UCSC Genome build hg19 The putative pathogenic mutations were analyzed computationally using the PolyPhen-2, SIFT, and MutationTaster algorithms. [14] [15] [16] These algorithms can distinguish mutations with functional effects from neutral mutations. The putative novel pathogenic variants that were reported neither in the 1000 Genome project database nor in the NCBI dbSNP database and the ExAC database were further confirmed.
| RESULTS
Sixteen unrelated patients with DCM or HCM diagnosis were studied. From total screened patients, 31.25% (5/16) were patients with HCM and 68.75% (11/16) were patients with DCM. The subgroup of males was larger because of supposed cardiomyopathy male predominance. 17 The mean age for all patients was 48±16 years, 65±8 years for females (4/16) and 42±14 years for males (12/16) . NYHA (New York Heart Association) functional classification system of heart failure was used, which places patients into one of four categories (I-IV)
based on how much they are limited during physical activity (www.
heart.org). The positive family history was confirmed only in one patient with dilated cardiomyopathy. Other patients were not aware of the occurrence of the disease in the family, but all of them were diagnosed as idiopathic cardiomyopathy. The cause may be variable expressivity (the clinical phenotype can vary among family members who all have the same mutation) or variable penetrance (sometimes, family members will carry a gene mutation but have completely normal cardiac function) and also age-related penetrance. The detailed characteristics of cardiomyopathy patients are shown in Table 2 . In all patients, the genetic pathogenesis of cardiomyopathy was previously unknown.
All successfully mapped sequence reads were analyzed in order to detect sequence variants. After filtering of data we finally work with 18 nonsynonymous variants, which were predicted by SIFT tool as damaging. Summary of nonsynonymous variants is shown in Table 3 .
These variants were detected in 16 analysed genes which can be 
| DISCUSSION
The first gene mutation identified to be causing heart disease was reported in 1993 18 ; since then, more than 1400 mutations that T A B L E 1 List of selected genes associated with cardiomyopathies
encode sarcomere proteins have been detected in at least 20 genes, 19 calcium-handling proteins, Z-disc proteins, etc. In this study, the whole exome sequencing was used to find cardiomyopathy associ- Nevertheless, a high coverage not necessarily indicates a true variant either.
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The criteria for variant calling were a read coverage higher than 30x. The functional impact of amino acid changes was predicted using three computational programs (PolyPhen2, SIFT and MutationTaster).
The usefulness of expanded gene testing is most obvious for overlapping clinical entities, such as HCM and DCM, which are each associated with more than 40 disease genes. 21 Restricting the genetic analysis to only frequently affected, well-established disease genes would ultimately risk overlooking of variants in genes with a prognostic impact, such as ANK2.
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In our study two variants previously described in the etiology of CMP were identified. We detected a rare variant (MAF=0.0008) rs34580776 (MYBPC3) in 2/16 patients (1 HCM and 1 DCM patient) with a potential functional effect on the protein (R/Q), which was also predicted by SIFT and MutationTaster. MYBPC3 gene encodes cardiac myosin binding protein C, which is found in cardiac muscle cells and is associated with the sarcomere. In particular, MYH7 and MYBPC3
sarcomere proteins mutations are most commonly related to HCM. 23 Mutation rs34580776 in the MYBPC3 gene was documented in previous studies on HCM and also in DCM patients.
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Another variant associated with CMP, but mainly with DCM was found in the gene RBM20 (RNA binding motif protein 20), which is highly expressed in cardiac tissues and regulates splicing by processing of pre-mRNA. 27 Transcript splicing is regarded as one of the primary mechanisms by which phenotypic variation is generated 28 and studies supported the role of RBM20 as a proximal regulator in a pathway that regulates cardiac morphology and as disease susceptibility locus for DCM. 29 Variant rs942077 in RBM20 was found in 3% of subjects with DCM, but the association between this variant and transplantation rate and frequency of implantable cardioverter defibrillator therapy has not been proven. 30 In our study, the variant rs942077 was identified in 10/11 DCM patients and 5/5 HCM patients.
From a total number of 18 variants we filtered six, which were predicted by SIFT as damaging, by PolyPhen2 as probably/possibly damaging and by MutationTaster as disease causing. Two of them were rare variants according to MAF value (MAF<0.01), which were not previously described in etiopathogenesis of CMP, but may be potential markers for CMP.
The rare variant rs148374985 is located in the MURC gene (muscle restricted coiled-coil), which encodes Z-line component protein predominantly expressed in the heart, activates RhoA/ROCK pathway implicated in heart failure, expression of atrial natriuretic peptide and regulates myofiber organization. arterial fibrillation,
